The 22nd Annual Anglonordic Life Science Conference is set to gather over 350 key delegates in London next April. This highly specialized event attracts leading drug discovery and technology companies from the UK, Nordic region, and across Europe, alongside prominent European investment firms. The conference kicks off with its signature, must-attend networking opportunity: a prestigious reception held in London the evening before the main conference day, ensuring immediate and valuable connections are made.

The last conference saw exceptional attendance, including 86 high-quality investor firms, solidifying its position as a major funding hub. The formal program featured focused panel discussions addressing critical European investment trends and technological advancements, complemented by 36 funding pitches delivered by cutting-edge biomedical and healthcare startups. Furthermore, the dedication to facilitating business was clear, with every available slot for 1:1 partnering fully booked throughout the day, underscoring the event’s efficacy as a deal-making platform.

Supported by M Ventures as the lead and founding sponsor, and featuring rich, engaging content devised and coordinated by Optimum Strategic Communications, Anglonordic stands out in the life sciences calendar. It is recognized as one of the top networking and partnering opportunities in the industry and is considered the unique R&D-to-investor conference in the UK, making it essential for anyone focused on innovation and funding in the sector.